Retroperitoneal fibrosis primary prevention

Retroperitoneal fibrosis Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating Retroperitoneal fibrosis from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Retroperitoneal fibrosis primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Retroperitoneal fibrosis primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Retroperitoneal fibrosis primary prevention
CDC on Retroperitoneal fibrosis primary prevention
Retroperitoneal fibrosis primary prevention in the news
Blogs on Retroperitoneal fibrosis primary prevention
Directions to Hospitals Treating Retroperitoneal fibrosis
Risk calculators and risk factors for Retroperitoneal fibrosis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Primary Prevention

If possible, avoid long-term use of medications that contain methysergide, which has been shown to cause retroperitoneal fibrosis. Methysergide is sometimes used to treat migraine headaches.